Cancel

Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma

STATEMENT OF NEED An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, inclu...
i3 Health

Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma

STATEMENT OF NEED Sarcomas, which represent 1% to 2% of adult cancers, are a rare, heterogeneous group of neoplasms originating in the connective tissue. Soft tissue sarcomas, which begin in the muscle, tendons, fat, lymph, blood vessels, and nerves, encompass more than 80 histological subtypes. Approximately 25% of patients develop metastatic disease after curative-intent surgery, and for these patients, treatment options are limited and prognosis is very poor. In recent decades, the ident...
i3 Health

Putting the Freeze on Cold Agglutinin Disease

STATEMENT OF NEED Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia (AIHA) in which antibodies cause hemolysis at cold temperatures, generally between 37º to 39º Fahrenheit. Approximately 1 in a million people are affected by CAD annually, with onset usually occurring between the ages of 40 and 80 years. Individuals commonly experience fatigue, dizziness, palpitations, and shortness of breath caused by the anemia; jaundice caused by degradation of hemoglobin i...
i3 Health

Managing Immune Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes: The Nurse’s View

STATEMENT OF NEED Immune checkpoint inhibitors, which alter immune regulatory pathways and promote cell-mediated destruction of tumor cells, have revolutionized the treatment of cancer in recent years, with numerous therapeutic agents approved and several targets under investigation (Chennamadhavuni et al, 2022). However, up to 90% of patients receiving immune checkpoint inhibitors experience immune-related adverse events, which can affect a wide variety of organ systems and can occur at any ...
i3 Health

Current Standards and New Directions in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura

STATEMENT OF NEED Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening thrombotic microangiopathy with a rapid onset and progression and a mortality rate of 10% to 20% with prompt treatment. Onset of aTTP is characterized by severe thrombocytopenia, microangiopathic hemolytic anemia, and a constellation of associated symptoms including hemorrhage, neurologic and renal manifestations, cardiac abnormalities, and mesenteric ischemia (Joly et al, 2017). Survivors of f...
i3 Health

Diagnosis and Management of Patients With Predominant Skin Symptoms

The educational design of this activity addresses the needs of allergy/clinical immunology, gastroenterology, dermatology, and hematology clinicians who manage patients with nonadvanced systemic mastocytosis. Nonadvanced systemic mastocytosis (SM) is a group of rare disorders characterized by mast cell accumulation that results in a significant and varied symptomatic burden to the patient. The most prevalent of these symptoms include gastrointestinal symptoms, dermatological symptoms, and ...
Integritas Communications

Navigating New Evidence in the Treatment of HER2-Expressing Metastatic Breast Cancer in Rural and Underserved Communities

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview Over the past decades, the emergence of novel targeted therapies in combination with endocrine therapy has improved outcomes for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. However, oncology clinicians in rural and ...
Postgraduate Institute for Medicine and RME Collaborative.

Navigating the Evolving Treatment Landscape of Renal Cell Carcinoma to Ensure Equitable Access to Quality Care

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview Therapeutic options for metastatic renal cell carcinoma (RCC) have expanded over the last decade and now include targeted therapies as well as immunotherapies. However, workforce shortages, low rates of recruitment into clinical trials, racial and socioeconomic inequities, a...
Talem Health and RME Collaborative.

How I Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)

In this point-counterpoint digital activity, two expert faculty discuss and debate treatment selection for patients with PNH through case-based scenarios. Faculty review mechanisms of action, clinical trial data, and real-world evidence supporting divergent treatment strategies for the presented cases. How do the experts make their initial treatment selections? Why might they choose a C5 inhibitor or a C3 inhibitor? How do they assess response to treatment, and what do they do when treatment r...
ACHL

Integrating PARP Inhibitors Into Treatment for Advanced Ovarian Cancer: Strategies for Improving Care and Outcomes

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview In recent years, the emergence of novel therapeutic agents has led to improved outcomes for patients with advanced and/or platinum-resistant ovarian cancer. Yet, even with improved treatment options, oncology teams in rural and underserved settings are challenged to provide ...
Postgraduate Institute for Medicine and RME Collaborative.

Internal Medicine Comprehensive Review and Update 2024 - LIVE STREAMING

Comprehensive, Evidence-Based Updates for Internal Medicine and Its Subspecialties This program, the 64th annual Internal Medicine Update from the leading clinical faculty of Harvard Medical School and Massachusetts General Hospital, provides comprehensive, high-yield instruction to ensure clinicians are current with the latest evidence and best practices to optimize patient care. This program covers the breadth of Internal Medicine subspecialties, including: • Cardiovascular Medicine ...
Harvard Medical School

Making the Call in Nonadvanced Systemic Mastocytosis Optimizing Multidisciplinary Management

Series Overview Nonadvanced systemic mastocytosis (SM) is a group of rare disorders characterized by mast cell accumulation that results in a significant and varied symptomatic burden to the patient. The most prevalent of these symptoms include gastrointestinal symptoms, dermatological symptoms, and recurrent anaphylaxis in response to a variety of triggers such as food, insect venom, and medications. In this Phone-a-Friend series, a multidisciplinary panel of faculty experts will address the...
Integritas Communications

Intensive Review of Internal Medicine - IN PERSON or LIVE STREAMING

The Acclaimed Clinical Update and Board Review With more than 150 lectures, case discussions, and board preparation sessions, this CME program is one of the most comprehensive reviews of internal medicine offered by the clinical faculty of Harvard Medical School. It offers accelerated learning: - For clinicians seeking a practical and comprehensive review that ensures you are up to date across all major fields of internal medicine: • Newer options for diagnosis: what to choose, w...
Harvard Medical School

Clinical Updates in Chronic Graft-versus-Host Disease and Applications for Academic and Community Practice

Target Audience The target audience for this activity are hematologists, oncologists, immunologists, and bone-marrow transplant specialists. Program Overview Chronic graft-versus-host disease (cGvHD) is a common, multi-symptom complication of allogeneic transplantation that severely affects patient well-being. While the medical systems and resources differ between academic and community healthcare settings, clinicians practicing in both environments would benefit from education about rece...
Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC (PQHE)

LET'S TALK: Tackling Complex Issues Regarding SM-AHN Management A Monday Morning Joe Online Educational Activity

Systemic mastocytosis (SM) is a group of rare disorders characterized by the accumulation of mast cells in internal tissues and organs. The pathogenesis of SM is linked to a characteristic exon 17 D816V mutation of the KIT gene. Systemic mastocytosis with associated hematologic neoplasms (SM-AHN) is an advanced subtype of SM that is associated with a shortened median survival time. Recent advances in the SM therapeutic landscape have led to the development of KIT-targeted treatment options; ho...
Integritas Communications

Treatment Considerations in Cutaneous Melanoma: From Early Stage to Late/Advanced Stage

Jason J. Luke, MD, discusses the impact of evolving therapies on the disease burden, survival, and treatment tolerability for patients with cutaneous melanoma. Recent clinical trial results and guideline updates for both perioperative and metastatic cutaneous melanoma are reviewed. To provide patient-centric care, Dr. Luke shares his expert insights and recommendations for individualizing treatment selection and sequencing, as well as providing supportive care and adverse event management.
Annenberg Center for Health Sciences at Eisenhower

Expanding the Benefit of Quality Improvement Programs: Sustainable Solutions to Achieve Therapeutic Goals for Patients with Myelofibrosis

Achieve measurable changes to improve your patients’ outcomes with this simple, systematic approach for quality improvement for application at any practice setting. Complete an assessment to understand where your practice’s performance falls relative to identified goals, which guides development of personalized action items. Access the framework and tools you need to measure your understanding.
ACHL

Therapeutic Advancements for the Treatment of High-Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life

Stay up to date on the evolving risk classification for myelodysplastic syndromes (MDS) and current treatment guidelines for patients with high-risk disease in this self-directed education with leading oncology experts. Expert commentary from Courtney DiNardo, MD from MD Anderson Cancer Center and Dr. Dan Pollyea from the University of Colorado School of Medicine provides insights on emerging therapies that could soon improve management of high-risk MDS. Be ready to incorporate these emerging ...
ACHL

Sustainable Solutions to Achieve Therapeutic Goals for Patients with Myelofibrosis

When it comes to treating your patients with myelofibrosis (MF), are you applying the latest guidance in practice? Evidence shows that it takes an average of 17 years for evidence to change practice but how can we incorporate treatment advances to improve patient outcomes today? This activity looks to bridge the chasm between education and implementation by framing available evidence and guideline recommendations for MF, including diagnosis, risk stratification, JAK inhibition, monitoring resp...
ACHL

Best Practices in Multiple Myeloma Care: Opportunities to Improve Outcomes in Community Settings

As nurses and APPs are well positioned to educate, support, and coordinate care for patients with multiple myeloma, having insight into the evolving trajectory of the disease will enhance their ability to provide quality patient care and identify and eliminate barriers. Addressing barriers to care remains key in ensuring access to novel therapies and improving quality of life. Having an understanding of the advances and increasing complexity of care of the patient with multiple myeloma will pr...
American Academy of CME

Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies

The expanding armamentarium of therapies for R/R MM shifts therapy selection from an algorithmic approach to an individualized strategy that requires consideration of the nature of relapse, prior therapies, treatment-related toxicities, as well as patient comorbidities and preferences. With the introduction of novel bispecific antibodies, specialists must learn how to optimally sequence these therapies and manage adverse events. To help clinicians navigate this complexity, individualized educa...
ACHL

The latest insights into rare blood disorders: Diagnosis and treatment strategies

Because immune-mediated rare blood disorders are uncommon, healthcare providers often lack the knowledge and experience necessary to identify, diagnose, and treat them in accordance with best practices. As a result, there are significant gaps in care, including delays in diagnosis and suboptimal treatment. To ensure that more patients with these rare disorders are offered quality, evidence-based care, it is essential that healthcare providers possess up-to-date information about best practices...
CMEology

Addressing Key Questions About BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma

ACTIVITY DESCRIPTION Though treatment advances have improved outcomes for most patients, MM remains an incurable disease characterized by continuous relapse. However, the treatment landscape for relapsed/refractory MM (RRMM) has expanded in recent years, and patients who relapse and/or become refractory to initial therapies are benefiting from the increasing availability of a diverse range of novel agents, including B-cell maturation antigen (BCMA)"targeted immunotherapies. These agents ...
Multiple Myeloma Research Foundation, RedMedEd, and Purdue University College of Pharmacy

Across the Compendium: Practical Pathways to Integrate Bispecific Antibodies Into Care for Patients With Relapsed/Refractory Multiple Myeloma

As the armamentarium of therapies for relapsed/refractory multiple myeloma (R/R MM) expands, several factors, including previous therapy, treatment-related toxicity, and comorbidities must be considered as part of clinical decision making. To assist the multidisciplinary treatment team in these efforts, and ensure patients are receiving cutting-edge cancer care, this immersive digital practice guide highlights best practices, clinical pearls, and strategies to overcome pitfalls in the administ...
ACHL

Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes

STATEMENT OF NEED Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ...
i3 Health

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map